Archives
-
Cardiac Biomarkers in Epileptic Baboons
2026-10-06
Szabó and colleagues used a pedigreed captive baboon model to examine whether epilepsy is associated with QT-interval abnormalities and altered heart rate variability. The study identified significantly prolonged QT and QTcF intervals, while the reduction in RMSSD was not statistically significant, supporting cardiac repolarization as a candidate SUDEP-related biomarker but not a standalone predictor.
-
Partial BACE1 Inhibition and Synaptic Transmission
2026-10-06
Satir et al. examined whether partial BACE inhibition could reduce amyloid-beta secretion without impairing neuronal communication. In primary rat cortical cultures, three inhibitors, including Lanabecestat (AZD3293), produced no detectable synaptic-transmission deficit when amyloid-beta secretion fell by less than 50%, whereas stronger inhibitory exposure was associated with reduced transmission. The findings support a bounded, assay-specific rationale for studying moderate amyloidogenic pathway modulation, while not establishing clinical efficacy or universal synaptic safety.
-
Amorolfine Hydrochloride and Fungal Cell Integrity
2026-10-05
Amorolfine Hydrochloride is an antifungal reagent for studying membrane-linked fungal physiology. This article connects its research value to evidence from budding-yeast ploidy studies while separating established findings from testable hypotheses in fungal cell membrane disruption and resistance research.
-
Metformin Hydrochloride and Fibrosis Evidence
2026-10-05
Metformin Hydrochloride is best known for metabolic research, but emerging evidence connects AMPK signaling with tissue fibrosis. This article examines the vocal fold study’s mechanistic contribution, evidence strength, and limits without treating preclinical findings as clinical proof.
-
DPPH Beyond Color: Translational Antioxidant Strategy
2026-10-04
DPPH is most valuable when treated as one layer of an evidence strategy rather than a stand-alone proxy for biological efficacy. This thought-leadership analysis connects DPPH-based radical scavenging measurements with orthogonal assays, metabolomics, and translational decision-making, using a 2026 Taihangia rupestris study as a case study.
-
Methoxy-X04 and Amyloid Imaging Evidence
2026-10-03
A source-grounded overview of Methoxy-X04 as a fluorescent amyloid beta probe, its conceptual relevance to plaque and microglial research, and the evidence boundaries surrounding a recent exercise–extracellular-vesicle study in Alzheimer’s disease mice.
-
Salvianolic Acid B: Reframing Fibrosis Research
2026-10-02
Salvianolic acid B, also known as Dan Shen Suan B, offers a mechanism-resolved way to investigate LH2/PLOD2-driven collagen maturation, matrix stiffening, and pulmonary fibrosis progression. This translational perspective connects compound handling with orthogonal fibrosis readouts and defines the evidence needed to move from an attractive natural product to a credible antifibrotic research strategy.
-
PP2A, Autophagy, and Candida Biofilm Drug Resistance
2026-10-01
The reference study identifies PP2A catalytic subunit PPH21 as a regulator of Candida albicans biofilm formation and antifungal drug resistance through Atg13 phosphorylation and Atg1-associated autophagy. Its genetic, pharmacologic, cellular, and mouse-infection experiments connect autophagy activation with stronger biofilm persistence and reduced treatment efficacy, while highlighting PP2A-dependent signaling as a possible intervention point.
-
Amphotericin B for Reproducible Cell Assays
2026-10-01
A scenario-based guide to using Amphotericin B (SKU B1885) in fungal, viability, proliferation, and cytotoxicity workflows. It connects sterol biology with practical controls for solvent handling, concentration selection, data interpretation, and product evaluation.
-
METTL16–SENP3–LTF Axis in HCC Ferroptosis
2026-09-30
Wang et al. identify a METTL16–SENP3–LTF regulatory axis that protects hepatocellular carcinoma cells from ferroptosis by altering mRNA stability, protein de-SUMOylation, and iron availability. The study integrates cellular, organoid, xenograft, genetically engineered mouse, and human-sample evidence, offering mechanistic targets for ferroptosis-based cancer research while highlighting important limits for pharmacological translation.
-
DAPT (GSI-IX): Mechanism, Uses & Limits
2026-09-30
DAPT, also called GSI-IX, is a selective γ-secretase inhibitor used to perturb amyloid precursor protein and Notch receptor processing. Its nanomolar benchmark values and context-dependent effects make it useful for Alzheimer's disease research, Notch signaling pathway studies, and cancer research, but assay-specific controls are essential.
-
Dual Luciferase Reporter Gene System for CENPI
2026-09-29
Learn how the Dual Luciferase Reporter Gene System can dissect CENPI-linked Wnt/β-catenin transcriptional regulation. This practical, evidence-grounded guide connects reporter design, normalization, and assay controls to mechanistic breast cancer research.
-
DAPT (GSI-IX) Workflow for Notch Research
2026-09-29
DAPT (GSI-IX) provides a controllable pharmacological method for testing how γ-secretase-dependent Notch and APP processing shapes cell fate, angiogenesis, and disease-relevant phenotypes. This workflow translates evidence from endothelial-cell and critical-limb-ischemia models into practical assay design, dose selection, controls, and troubleshooting.
-
1-myristoylglycerophosphocholine in Lipid Signaling
2026-09-28
Use 1-myristoylglycerophosphocholine, also known as 14:0 Lyso-PC, as a defined lysophospholipid probe for fibroblast activation, lipid signaling pathway analysis, and smooth muscle assays. This workflow separates species-specific effects from pooled LysoPC observations while addressing solvent, stability, dosing, and assay-normalization challenges.
-
FPS-ZM1 for RAGE-Linked Viability Assays
2026-09-28
A practical guide to using FPS-ZM1 (SKU C3723) as a RAGE inhibitor in cell viability and stress experiments. It covers compound handling, assay controls, interpretation of emerging RAGE/POMC findings, and evidence-aware product selection.